These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 19213563)

  • 1. The use of tamoxifen and raloxifene for the prevention of breast cancer.
    Wickerham DL; Costantino JP; Vogel VG; Cronin WM; Cecchini RS; Ford LG; Wolmark N
    Recent Results Cancer Res; 2009; 181():113-9. PubMed ID: 19213563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Lippman SM; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
    JAMA; 2006 Jun; 295(23):2727-41. PubMed ID: 16754727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
    Vogel VG; Costantino JP; Wickerham DL; McCaskill-Stevens W; Clarfeld RB; Grant MD; Wolmark N
    J Natl Cancer Inst Monogr; 2010; 2010(41):181-6. PubMed ID: 20956826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.
    Freedman AN; Yu B; Gail MH; Costantino JP; Graubard BI; Vogel VG; Anderson GL; McCaskill-Stevens W
    J Clin Oncol; 2011 Jun; 29(17):2327-33. PubMed ID: 21537036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
    Land SR; Wickerham DL; Costantino JP; Ritter MW; Vogel VG; Lee M; Pajon ER; Wade JL; Dakhil S; Lockhart JB; Wolmark N; Ganz PA
    JAMA; 2006 Jun; 295(23):2742-51. PubMed ID: 16754728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.
    Vogel VG
    Expert Rev Anticancer Ther; 2009 Jan; 9(1):51-60. PubMed ID: 19105706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From adjuvant therapy to breast cancer prevention: BCPT and STAR.
    Dunn BK; Ford LG
    Breast J; 2001; 7(3):144-57. PubMed ID: 11469927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts.
    Vogel VG
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4413s-4418s; discussion 4411s-4412s. PubMed ID: 11916233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P-1).
    Wolmark N; Dunn BK
    Ann N Y Acad Sci; 2001 Dec; 949():99-108. PubMed ID: 11795386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
    Cancer Prev Res (Phila); 2010 Jun; 3(6):696-706. PubMed ID: 20404000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Wolmark N
    Clin Breast Cancer; 2002 Jun; 3(2):153-9. PubMed ID: 12123540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR).
    Runowicz CD; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Ford LG; Vogel VG; Wolmark N
    Am J Obstet Gynecol; 2011 Dec; 205(6):535.e1-5. PubMed ID: 21872200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.
    Reimers LL; Sivasubramanian PS; Hershman D; Terry MB; Greenlee H; Campbell J; Kalinsky K; Maurer M; Jayasena R; Sandoval R; Alvarez M; Crew KD
    Breast J; 2015; 21(4):377-86. PubMed ID: 25879521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM
    Clin Cancer Res; 2003 Jan; 9(1 Pt 2):495S-501S. PubMed ID: 12538506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoprevention for high-risk women: tamoxifen and beyond.
    Fabian CJ; Kimler BF
    Breast J; 2001; 7(5):311-20. PubMed ID: 11906441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
    Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG
    J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of raloxifene and tamoxifen by breast cancer risk level in a Medicare-eligible cohort.
    Pinsky PF; Miller E; Heckman-Stoddard B; Minasian L
    Am J Obstet Gynecol; 2018 Jun; 218(6):606.e1-606.e9. PubMed ID: 29630889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of antiestrogens for prevention of breast cancer.
    Reddy P; Chow MS
    Am J Health Syst Pharm; 2000 Jul; 57(14):1315-22; quiz 1323-5. PubMed ID: 10918921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk versus Benefit of Chemoprevention among Raloxifene and Tamoxifen Users with a Family History of Breast Cancer.
    Anderson C; Nichols HB; House M; Sandler DP
    Cancer Prev Res (Phila); 2019 Nov; 12(11):801-808. PubMed ID: 31431499
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.